Review article: Aspirin, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-1 sparing agents

Alimentary Pharmacology and Therapeutics Symposium Series

Volumn 1, Issue 1, 2005, Pages 2-5

  Weaver, A L ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; LUMIRACOXIB; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB; VALDECOXIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LOW DRUG DOSE; OSTEOARTHRITIS; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STROKE; UNITED STATES;

EID: 26044442024     PISSN: 17466334     EISSN: 17466342     Source Type: Journal    
DOI: 10.1111/j.1746-6342.2005.00012.x     Document Type: Conference Paper

References (22)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
2. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74.
3. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127: 395-402.
4. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet 2004; 364: 639-40.
5. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
6. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal anti-inflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2433-40.
7. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-96.
8. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
9. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9.
10. Merck Announces Voluntary Worldwide Withdrawal of VIOXX® [press release]. NJ: Whitehouse Station, September 30, 2004. Available at: http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp.
11. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. Natl Vital Stat Rep 2001; 49: 1-113.
12. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-72.
13. US Preventive Services Task Force. Summaries for patients. Aspirin for the prevention of heart attacks in people without previous cardiovascular events: recommendations from the United States preventive services task force. Ann Intern Med 2002; 136: 155.
14. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-91.
15. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
16. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-4.
17. Kim C, Beckles GL. Cardiovascular disease risk reduction in the behavioral risk factor surveillance system. Am J Prev Med 2004; 27: 1-7.
18. Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med 2004; 164: 1243-6.
19. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-6.
20. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95: 2218-24.
21. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000; 284: 1247-55.
22. Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003; 42 (Suppl. 3): iii23-31.